Contact

All of our greatest achievements have started with but a conversation. Whether you're an investor interested in exploring our portfolio of new opportunities in greater depth or if you're an entrepreneur or like-minded professional looking for that ideal relationship, taking that step towards a partnership with BVC starts with you. We look forward to hearing from you.

Submit Your Business Plan

We welcome the opportunity to review your business. If you would like to submit an executive summary or business plan, clicking "Submit Plan" below will take you to the appropriate form. Please note that we have a preference for executive summaries as a first contact. If we need to see the plan before deciding on next steps, we will contact you.

Submit Plan
close

ThirdStream BioScience

Back to Portfolio

ThirdStream BioScience
TSB is a Florida corporation that has acquired and is developing a novel topical antimicrobial technology. The technology allows for an unprecedented combination of safety, broad-spectrum antimicrobial efficacy against bacteria, viruses and fungi, and clinically significant  persistence. Yet it is benign to the skin and the environment. The technology has already been proven safe and effective on humans via limited approvals in Europe.

The technology was originally licensed from Proctor &Gamble. It has been substantially improved and further developed by TSB. Key patents have been issued on the improvements. Due to a series of interactions with P&G during 2006 and 2007, TSB owes P&G substantially no royalties or milestone payments on the newer improved versions.

The technology has two principal uses. One is as a persistent hand sanitizer. The major hand hygiene markets are in healthcare (prevention of bacterial infections such as MRSA or VRE), and public heath (prevention of colds and flus). UK approvals for public health included prevention of colds and flus, with 99% kill of bacteria and virus on hands for up to 3 hours, while safe for use on children as well as adults. The other principal use is topical therapy for skin diseases such as acne vulgaris or inflammatory  rosacea. Both of these markets are substantially over $1 billion globally.

The company presently has a written term sheet for a transaction with regard to  topical therapeutics, and is in discussions concerning hand hygiene transactions.
  • Industry: Biotech
  • Location: Chicago, IL

Batterson Venture Capital • 2017 © Copyright • All Rights Reserved